Date | Time | Source | Announcement |
---|---|---|---|
10 Mar 2008 | 07:02 AM | Phase III Trist Study | |
10 Mar 2008 | 07:01 AM | Preliminary Results | |
29 Feb 2008 | 11:43 AM | Total Voting Rights Update | |
20 Feb 2008 | 07:00 AM | Phase III Trist Study | |
19 Feb 2008 | 04:22 PM | Holding(s) in Company | |
15 Feb 2008 | 09:05 AM | Major Interest In Shares | |
13 Feb 2008 | 12:15 PM | Major Interest in Shares | |
07 Feb 2008 | 07:00 AM | Notification of Results | |
01 Feb 2008 | 10:40 AM | Notification of Shares | |
31 Jan 2008 | 08:57 AM | Total Voting Rights | |
30 Jan 2008 | 08:00 AM | Notifcation of Shares | |
23 Jan 2008 | 09:16 AM | Major Interest in Shares | |
22 Jan 2008 | 07:00 AM | Development Milestone | |
18 Jan 2008 | 12:53 PM | Notification of Shares | |
07 Jan 2008 | 07:00 AM | Exclusive License Agreement | |
18 Dec 2007 | 01:35 PM | Interest In Shares | |
13 Dec 2007 | 07:00 AM | Phase I/II Trial | |
10 Dec 2007 | 12:28 PM | Major Interest in Shares | |
10 Dec 2007 | 07:00 AM | Trovax Phase III Trial | |
05 Dec 2007 | 01:33 PM | Scrip's Deal of the year | |
29 Nov 2007 | 10:51 AM | techMARK Award | |
16 Nov 2007 | 11:18 AM | Block Listing | |
09 Nov 2007 | 07:00 AM | Broker Announcement | |
26 Oct 2007 | 07:01 AM | Patent Infringement Dispute | |
25 Oct 2007 | 11:27 AM | Director/PDMR Shareholding | |
25 Oct 2007 | 07:01 AM | Business Update | |
22 Oct 2007 | 02:57 PM | Director Shareholdings | |
28 Sep 2007 | 03:25 PM | Holding(s) in Company | |
11 Sep 2007 | 07:00 AM | Milestone in Trovax | |
11 Sep 2007 | 07:00 AM | Interim Results | |
31 Aug 2007 | 03:39 PM | Holding(s) in Company | |
31 Aug 2007 | 10:26 AM | TVR Update | |
30 Aug 2007 | 09:10 AM | Holding(s) in Company | |
07 Aug 2007 | 07:00 AM | Notice of Results | |
03 Aug 2007 | 04:33 PM | Holding(s) in Company | |
02 Aug 2007 | 03:38 PM | Holding(s) in Company | |
02 Aug 2007 | 07:02 AM | Phase II Clinical Trial Data | |
31 Jul 2007 | 03:05 PM | Total Voting Rights | |
25 Jul 2007 | 07:00 AM | DSMB Interim Analysis-TroVax | |
06 Jul 2007 | 07:00 AM | License Agreement | |
02 Jul 2007 | 07:00 AM | Lentivector Licence | |
29 Jun 2007 | 04:17 PM | Total Voting Rights | |
28 Jun 2007 | 12:39 PM | Holding(s) in Company | |
28 Jun 2007 | 12:29 PM | Notification of Interest | |
22 Jun 2007 | 12:43 PM | Viragen Update | |
18 Jun 2007 | 07:01 AM | Health Care Conference | |
18 Jun 2007 | 07:00 AM | Holding(s) in Company | |
04 Jun 2007 | 07:01 AM | Phase II Trovax data at ASCO | |
31 May 2007 | 05:38 PM | Total Voting Rights Update | |
29 May 2007 | 07:01 AM | ASCO data |
Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.
Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.
Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.